Janelle Perez and the NYU Rory Meyers group confirmed Friday that the monocyte epigenetic-age assay reported in their May 4 Journals of Gerontology paper has entered a prospective validation cohort. [1] The plan, registered in the NIH ClinicalTrials.gov database earlier this week, enrols 1,200 adults aged 60 and older across four U.S. sites, with primary endpoint the 18-month incidence of non-somatic depression — anhedonia, hopelessness, feelings of failure — predicted from a single baseline blood draw. [2]

The paper's Friday brief on the original 440-person finding carried the structural news: monocyte clocks predicted the phenotype where multi-tissue clocks did not, and the WIHS sample was older, immunocompromised, and ethnically specific. The validation cohort is the answer to the second concern. Site enrollment will draw from primary-care registries at Penn, Vanderbilt, the University of Washington, and Emory — a broader population, treatment-stratified, with prospective rather than cross-sectional follow-up.

The mechanism that the assay indexes is straightforward to state and difficult to deploy. Monocytes are circulating immune cells whose epigenetic clocks appear to age faster in people who go on to develop late-life cognitive depression. The hypothesis is that chronic peripheral inflammation drives both the aging signal and the symptoms. The assay does not test the hypothesis; it tests whether the signal is reliable enough to time clinical intervention. [3]

First validation results are expected in the third quarter of 2027. The clock starts now.

-- KENJI NAKAMURA, Tokyo